Addition of cytarabine improves outcome for PCNSL patients

Submitted by Ross Bonander Tue 03/02/2010

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Noting that the prognosis for most patients with primary central nervous system lymphoma is poor regardless of therapy and that only a minority of patients achieve a complete response to current chemotherapy regimens, Mayo Clinic researchers carried out a randomized phase II clinical trial in which high-dose cytarabine was added to high-dose methotrexate .

According to their findings, published in Nature Reviews Clinical Oncology, the regimen both increased the complete response rate and improved patient outcome.

By Ross Bonander

Source: Hematology: Trials and tribulations in primary CNS lymphoma

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.